Scarica l'app Stockscreener
8.33
1.65%
-0.14
Dopo l'orario di chiusura:
8.36
0.03
+0.36%
Precedente Chiudi:
$8.47
Aprire:
$8.43
Volume 24 ore:
1.16M
Relative Volume:
1.03
Capitalizzazione di mercato:
$2.58B
Reddito:
$2.50B
Utile/perdita netta:
$-168.69M
Rapporto P/E:
-416.50
EPS:
-0.02
Flusso di cassa netto:
$124.24M
1 W Prestazione:
-9.46%
1M Prestazione:
-2.91%
6M Prestazione:
+22.14%
1 anno Prestazione:
+83.89%
Intervallo 1D:
$8.18
$8.47
Intervallo di 1 settimana:
$8.18
$9.475
Portata 52W:
$4.16
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Confronta AMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| AMRX | 8.33 | 2.58B | 2.50B | -168.69M | 124.24M | -0.02 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 16.3% in October - MarketBeat
Sandoz, Amneal Get Mixed Ruling in State Drug Price-Fixing Case - Bloomberg Law
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Amneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growth - Investing.com
Amneal stock target gets a boost, overweight on strong Q3 results - Investing.com Canada
Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Piper Sandler Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price - MarketBeat
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price - Simply Wall St
Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Earnings call: Amneal Pharmaceuticals sees a 13% revenue surge in Q3 2024 - Investing.com
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates - MSN
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q3 2024 Earnings Call Transcript - MSN
Nisa Investment Advisors LLC Sells 221,848 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharma A earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Amneal Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Amneal: Q3 Earnings Snapshot - The Washington Post
Amneal Reports Third Quarter 2024 Financial Results - BioSpace
Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts - Benzinga
Amneal Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2024 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024 - Marketscreener.com
Amneal Pharmaceuticals reports Q3 adjusted EPS 16c, consensus 13c - TipRanks
Amneal Pharmaceuticals Swings to 3Q Loss While Sales Climb - MarketWatch
Teva Fails To Convince Judge Inhaler Patents Require Drug - Law360
Amneal (AMRX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - MSN
Zacks.com featured highlights include Amneal Pharmaceuticals, Cronos Group, Carriage Services, Business First Bancshares and Amphenol - Yahoo Finance
Panel Discussion on ‘Next growth frontiers for India Pharma Inc' - Express Pharma
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline - MSN
Amneal Pharmaceuticals (AMRX) Scheduled to Post Earnings on Friday - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Yahoo Finance
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Top Companies in the Phenazopyridine Market Set for Success - openPR
Assenagon Asset Management S.A. Purchases 642,065 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Amneal wins FDA approval for nerve agent pretreatment - Investing.com
Amneal wins FDA approval for nerve agent pretreatment By Investing.com - Investing.com Australia
Amneal Pharmaceuticals Gets FDA Approval for Pyridostigmine Bromide - MarketWatch
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets - Business Wire
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 12-Month HighWhat's Next? - MarketBeat
SG Americas Securities LLC Invests $531,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
AMRX Stock Soars to 52-Week High, Reaching $8.94 - Investing.com
Cardiac Sarcoidosis Drugs Global Market Report |Hikma Pharmaceuticals PLC, Mylan N.V, Amneal Pharmaceuticals LLC, Mallin – IndiaPolitics.com - IndiaPolitics.com
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Azathioprine Tablets Industry to Witness an Outstanding Growth by 2030 |Mylan, Zydus Pharmaceuticals, Amneal Pharmaceuti – IndiaPolitics.com - IndiaPolitics.com
Glycopyrrolate Injection Market Growth Report |Accord Healthcare, Advanz Pharma, American Regent, Amneal Pharmaceuticals – IndiaPolitics.com - IndiaPolitics.com
Amneal Pharma to build two new manufacturing facilities in Ahmedabad - Medical Dialogues
Amneal to Build Two Manufacturing Facilities in Ahmedabad, Gujarat - Chemical Industry Digest
Weight loss drugs to be produced in two new plants in India - Investment Monitor
Sei Investments Co. Grows Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):